Cabozantinib (XL184) at 40 mg in patients with metastatic castration resistant prostate cancer (mCRPC): Results of a phase 2 non-randomized expansion cohort (NRE) Meeting Abstract
| Authors: | de Bono, J. S.; Smith, M. R.; Rathkopf, D.; Corn, P. G.; Mukherji, D.; Harzstark, A. L.; Sartor, O. A.; Smith, D. C.; Tunariu, N.; Sweeney, C. |
| Abstract Title: | Cabozantinib (XL184) at 40 mg in patients with metastatic castration resistant prostate cancer (mCRPC): Results of a phase 2 non-randomized expansion cohort (NRE) |
| Meeting Title: | 37th Congress of the European Society for Medical Oncology (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 23 |
| Issue: | Suppl. 9 |
| Meeting Dates: | 2012 Sep 28-Oct 2 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2012-09-01 |
| Start Page: | ix296 |
| Language: | English |
| ACCESSION: | WOS:000309409001378 |
| PROVIDER: | wos |
| PUBMED: | 23012731 |
| DOI: | 10.1093/annonc/mds400 |
| Notes: | Meeting Abstract: 897O -- "Source: Wos" |
